NCT07033819 2026-02-27
Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
Clinical Trials
34 trialsNCT07353684 2026-01-20
Adebrelimab, Apatinib & SOX for Conversion Therapy in Advanced Gastric/GEJ Cancer
Beijing Friendship Hospital
Phase 2 Recruiting
NCT07311408 2025-12-31
SHR-2554
China Medical University, China
Phase 2 Recruiting
NCT06576973 2025-12-02
Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT07157969 2025-12-01
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT06925516 2025-11-28
ACADEMY
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT06349317 2025-09-29
Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT
Meng Chao Hepatobiliary Hospital of Fujian Medical University
Phase 2 Recruiting
NCT06145308 2025-09-15
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Peking Union Medical College
Phase 2 Recruiting
NCT05934331 2025-09-12
A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
LaNova Medicines Limited
Phase 2 Recruiting
NCT07105748 2025-08-17
TASK-05
Fudan University
Phase 2 Recruiting
NCT06831175 2025-06-03
Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma
West China Hospital
Phase 2 Recruiting
NCT06429696 2025-05-28
PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer
Nanfang Hospital, Southern Medical University
Phase 2 Recruiting
NCT04072042 2025-05-14
BIOVAS
Ruijin Hospital
Phase 2 Recruiting
NCT06483282 2025-04-15
A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer
Zhejiang Cancer Hospital
Phase 2 Recruiting
NCT05512481 2025-03-03
Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma
Peking University Cancer Hospital & Institute
Phase 2 Recruiting
NCT05192798 2025-02-27
Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC
The First Affiliated Hospital of Bengbu Medical University
Phase 2 Recruiting
NCT06749691 2024-12-27
LIAES
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT06418594 2024-12-10
Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis
Beijing 302 Hospital
Phase 2 Recruiting
NCT06482086 2024-12-05
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
West China Hospital
Phase 2 Recruiting
NCT05594095 2024-10-04
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Fudan University
Phase 2 Recruiting
NCT06454578 2024-08-01
Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection
Qilu Hospital of Shandong University
Phase 2 Recruiting
NCT05412589 2024-07-31
mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT06475209 2024-06-26
Adebrelimab + Apatinib in SCLC Maintenance Therapy
Tang-Du Hospital
Phase 2 Recruiting
NCT04834674 2024-06-25
DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma
Sichuan Cancer Hospital and Research Institute
Phase 2 Recruiting
NCT06415669 2024-05-29
A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
NCT06280508 2024-04-23
Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT06296563 2024-04-17
Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT06363825 2024-04-17
A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma
Fujian Medical University
Phase 2 Recruiting
NCT06339619 2024-04-01
Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT05905887 2024-02-28
Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor
Asan Medical Center
Phase 2 Recruiting
NCT05759572 2024-02-06
Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer
Fudan University
Phase 2 Recruiting
NCT05069857 2023-11-22
Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients
Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
NCT06099821 2023-10-26
KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade
Peking University Cancer Hospital & Institute
Phase 2 Recruiting
NCT05447702 2023-05-22
Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
West China Hospital
Phase 2 Recruiting